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ABSTRACT: As a way to address the flaws of traditional payment methods, like fee-for-service 
and capitation, the authors of this report suggest a new payment model, based on evidence-
informed case rates (ECRs). Under this system, providers are paid a single, risk-adjusted payment 
across inpatient and outpatient settings to care for a patient diagnosed with a specific condition. 
Working with experts in the health care field, the authors selected 10 conditions for ECR 
development, examining issues like diagnosis, services covered by the ECR, and criteria for 
successful completion of care. This new model, say the authors, can improve health care quality, 
lower administrative burden, enhance transparency, and support a patient-centered, consumer-
driven environment. To further promote quality care, the ECR model calls for a portion of the 
payment to be withheld and re-distributed based on provider performance on measures of clinical 
process, outcomes of care, and patient experiences. 
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 EXECUTIVE SUMMARY 
 
The flaws of the traditional fee-for-service and capitation systems are well known. 
The former—which involves separate payments for each service—has been closely 
associated with the rapid rise of health insurance premiums, while the latter—which 
provides a flat fee per patient—can put providers at risk by providing insufficient funds to 
cover the cost of services rendered. In the United States, both systems have failed to 
promote coordination among providers or high-quality outcomes for patients. 
 
A new payment model, based on evidence-informed case rates (ECRs), attempts 
to address these failings. An ECR is a single, risk-adjusted, prospective (or retrospective) 
payment given to providers across inpatient and outpatient settings to care for a patient 
diagnosed with a specific condition. Payment amounts are based on the resources required 
to provide care as recommended in well-accepted clinical guidelines. The ECR model 
was developed by Prometheus Payment, a nonprofit corporation focused on developing a 
new health care payment model designed to improve health care quality, lower 
administrative burden, enhance transparency, and support a patient-centered, consumer-
driven environment.1 To further promote quality care, the Prometheus ECR model calls 
for a portion of the payment to be withheld and re-distributed based on provider 
performance on measures of clinical process, outcomes of care, and patient experience 
with care received. 
 
To model ECRs in a way that would be credible, realistic, and accurately reflect 
the clinical delivery of care, Prometheus gathered experts in the field and convened five 
working groups, consisting of medical professionals, health care researchers, and data 
modeling experts. The working groups selected 10 conditions for ECR development, 
looking at criteria like prevalence, costs, treatment variation, coordination, and 
reimbursement, among others. Then, they developed the scope of each ECR, by 
examining issues like the standard workup required to diagnose the condition, the services 
covered by the ECR, and criteria for successful completion of care. 
 
To develop an estimate of the base ECR payment, the groups walked a typical 
patient step-by-step through the relevant clinical practice guidelines, using the following 
four questions to match costs with guidelines: 
 
1. What are the actual resources (e.g., equipment, facilities, supplies) used to provide 
the recommended care? 
2. Who is most likely to use those resources? 
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 3. Where might this care happen most often? 
4. How long will it take (using surrogates of evaluation and management visits 
for time)? 
 
Table ES-1 shows the visits required to treat stage III colorectal cancer, based on the 
National Comprehensive Cancer Network’s practice guidelines 
 
 
Table ES-1. Visits Required to Treat Stage III Colorectal Cancer
Activity Frequency* Person 
Colonoscopy 1 Gastroenterologist and 
primary care provider 
counseling on need for 
colonoscopy 
Visit to review biopsy 1 Gastroenterologist 
Appointment regarding surgery 1 Surgeon 
Hospital stay and surgery 3 to 5 days Surgeon and hospital staff 
Review data for stage III disease 1 Medical oncologist 
Visit social worker 1 Social worker 
Visit chemo nurse for teaching 1 Chemotherapy nurse 
Decide on drug therapy 1 Medical oncologist 
Lab for pre-chemo CBC, CMP, liver, CEA 1 Lab 
Meet with clinical trial staff regarding protocol 1 Trial staff 
Chemotherapy and follow-up visit every 
two weeks 
24 Medical oncologist, chemo 
nurse 
Potential problems: nausea, diarrhea, fever, etc. 3 Medical oncologist, nurse 
One month post therapy: review drug therapy 
and survivorship likelihood 
1 Medical oncologist 
Follow-up visit every 3 months 4 Medical oncologist 
Disease and case management Ongoing Medical oncologist and/or 
primary care provider 
* Frequency refers to visits unless bed days are specified for hospital stays. 
Source: Authors’ analysis. 
 
 
For each condition, the working groups also identified a set of common 
complications that will change the services required. Future data modeling efforts will 
determine how the identified complications change the total cost of care. As complications 
develop, both the scorecard and the price paid for services rendered will change accordingly. 
 
An essential component of the ECR is the performance withhold. Provider 
performance will be tracked using two methods: 1) the Prometheus scorecard, which is 
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 currently being designed, will include measures of care process, outcomes, and patient 
experience and 2) normal claims activity. Tracking claims can play an important a role in 
assessing provider performance—as much as the scorecard—because appropriate 
performance on a condition can potentially only be known by looking at what services 
were delivered (or not delivered) to the patient. For example, measuring the right care 
for back pain is effectively accomplished by using claims data to identify services that 
should (and, more important, should not) have been provided. Conversely, depression 
typically has very few encounters, which provide limited detail on whether the patient’s 
status has changed. In this case, a patient’s status using a standardized clinical assessment 
tool is necessary. 
 
Next steps in developing and implementing ECRs include data modeling 
activities; determining which conditions merit development of new ECRs, based on 
availability of guidelines and potential impact on the payment system; and determining 
how best to keep ECRs updated as clinical guidelines change. In 2007, Prometheus will 
select up to four pilot sites and work with local stakeholders to prepare each site for 
implementation. Current candidates include Brockton, Mass.; Chicago; Memphis, Tenn.; 
Philadelphia; and San Francisco. Prometheus also expects to develop an additional 50 to 
60 ECRs during the next three years to increase the scope of the pilots and cover an 
increasing portion of the total care delivered in any community. 
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 EVIDENCE-INFORMED CASE RATES: 
A NEW HEALTH CARE PAYMENT MODEL 
 
 
INTRODUCTION 
The flaws of the traditional fee-for-service and capitation systems are well known. The 
former—which involves separate payments for each service—has been closely associated 
with the rapid rise of health insurance premiums, while the latter—which provides a flat 
fee per patient—can put providers at risk by providing insufficient funds to cover the cost 
of services rendered. In the United States, both systems have failed to promote 
coordination among providers or high-quality outcomes for patients. 
 
A new payment model, based on evidence-informed case rates (ECRs), attempts 
to address these failings. An ECR is a single, risk-adjusted, prospective payment given to 
providers across inpatient and outpatient settings to care for a patient diagnosed with a 
specific condition. Payment amounts are based on the resources required to provide care 
as recommended in well-accepted clinical guidelines. The ECR model was developed by 
Prometheus Payment, a nonprofit corporation focused on developing a new health care 
payment model designed to improve health care quality, lower administrative burden, 
enhance transparency, and support a patient-centered, consumer-driven environment. To 
further promote quality care, the Prometheus model calls for a portion of the payment to 
be withheld and re-distributed based on provider performance on measures of clinical 
process, outcomes of care, and patient experience with care received. 
 
The goal of ECRs is to limit both underuse and overuse, eliminate unwarranted 
variation, reduce risk selection problems that occur when providers receive the same 
payment to treat different types of patients, promote clinical integration between providers 
across disparate settings, and deliver recommended, high-quality care. 
 
To model ECRs in a way that would be credible, realistic, and accurately reflect 
the clinical delivery of care, Prometheus gathered experts in the field and convened five 
working groups, consisting of medical professionals, health care researchers, and data 
modeling experts. The goal of each group was to deliver one or more fully constructed 
ECRs. Specifically, the groups were charged with: 
 
• choosing the conditions for ECR development; 
• selecting clinical practice guidelines for those conditions; 
• determining the natural boundaries of the ECR; 
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 • providing a rigorous estimate of the base of the ECR, including the total units 
of service and the type of provider responsible for delivering those services; 
• establishing a reasonable set of performance measures that should be used to 
evaluate the clinical performance of providers delivering the services included 
in the ECR; 
• participating in and supervising the data modeling of the ECR to determine 
the extent to which the results were valid; and 
• creating estimates for the warranted variation of services that should be added 
to the base. 
 
SELECTING CONDITIONS FOR ECR DEVELOPMENT 
The working groups selected 10 conditions for ECR development (Table 1).2 With an 
eye toward a future pilot program, discussion centered on the following selection criteria: 
 
1. Conditions have high prevalence or high cost per event. 
2. There is wide variation in the treatment of the condition. Team members identified 
conditions where empirical data suggest treatment does not always follow the best 
available clinical evidence. 
3. Treatment of the condition requires coordination among multiple providers. Lack of 
coordination is a serious problem in the American health care system that lowers 
the quality of care patients receive.3 By choosing conditions that cross inpatient and 
outpatient settings, the working groups sought to identify situations where ECRs 
could promote coordination and reduce underuse, overuse, and misuse of services. 
4. Treatment of the condition requires services that are not currently reimbursed. Critics of the 
current system suggest that when it comes to conditions requiring frequent follow-
up, many health plans fail to adequately reimburse for necessary services such as 
case management and time spent providing patient care outside the office setting. 
In theory, ECRs should help solve these problems by providing a full accounting 
of the costs required to deliver all services in line with the best available evidence. 
5. Condition has clear boundaries. For some conditions, choosing a beginning and end 
state can be a difficult and somewhat arbitrary choice. Such conditions may not be 
good models for a set of pilot ECRs. With certain exceptions, the working groups 
agreed that the first set of ECRs should focus on conditions for which beginning 
and end points could be easily documented by clinicians and would not become 
issues of contention.4 
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 6. Clinical practice guidelines exist for the condition. The working groups built their ECRs 
based on clinical practice guidelines. If a condition does not have a well-accepted 
set of clinical practice guidelines, there may not be sufficient evidence or expert 
consensus to make a strong case for the more standardized levels of care that ECRs 
should promote. 
 
 
Table 1. Conditions Selected by Working Groups 
Working Group Conditions Guidelines Chosen 
Cancer • Colon cancer 
• Non-small-cell lung cancer 
National Comprehensive Cancer 
Network 
Cardiac care • Mitral valve regurgitation 
• Non-ischemic stage C 
congestive heart failure 
• ST segment elevated 
myocardial infarction  
American College of Cardiology/ 
American Heart Association 
Chronic care • Depression 
• Diabetes mellitus type 2 
Institute for Clinical Systems 
Improvement  
Orthopedics • Knee replacement 
• Hip replacement 
No one set chosen 
Preventive care • All preventive care Institute for Clinical Systems 
Improvement and U.S. Preventive 
Services Task Force Guidelines 
Source: Authors’ analysis. 
 
 
For several of the conditions selected, research suggests there are significant 
opportunities to promote increased compliance with recommended care (Table 2). Other 
conditions are expensive to treat or costly if not treated properly. For example, depression 
treatment has a very high cost impact, in terms of medical management and productivity, 
on both employers and society overall, making the condition a good candidate for 
ECR development. 
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 Table 2. Adherence to Quality Indicators in 12 U.S. Metropolitan Areas 
Condition Number of Indicators 
Percentage of 
Recommended Care 
Received (95% C.I.) 
Congestive heart failure 36 63.9 (55.4–72.4) 
Depression 14 57.7 (55.2–60.2) 
Orthopedic conditions 10 57.2 (50.8–63.7) 
Colorectal cancer 12 53.9 (47.5–60.4) 
Diabetes mellitus 13 45.4 (42.7–48.3) 
Source: E. A. McGlynn et al., “The Quality of Health Care Delivered to Adults in the United States,” 
New England Journal of Medicine, June 26, 2003 348(26):2635–45. 
 
 
DETERMINING THE NATURAL BOUNDARIES OF ECRS 
To finalize the scope of each ECR (i.e., to determine when it begins, when it ends, and 
when it should no longer be in force) working groups focused on four key questions: 
 
1. What is the clinical description of a typical patient covered by the core ECR? 
2. What is the standard workup required to diagnose the condition and establish the 
appropriateness and scope of the services covered by the ECR? 
3. What are the criteria that must be met for a typical patient to be eligible for 
coverage under the ECR? 
4. What are the criteria for successful completion of care for a typical patient covered 
by the ECR? 
 
Table 3 lists the responses to these questions for ST Segment Elevated Myocardial 
Infarction (STEMI). 
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 Table 3. Natural Boundaries for 
ST Segment Elevated Myocardial Infarction
Boundary Description 
Clinical 
description of a 
typical patient 
A 64-year-old male without a prior history of ischemic heart disease has 
the acute onset of sub-sternal chest pain that radiates into his left arm and 
jaw. He presents to the emergency department within one hour of the 
onset of pain. He has no prior history of any similar chest pain. 
 
Physical examination reveals blood pressure is 145/85, pulse is 105 and 
regular, and respiratory rate is 28. He is anxious and diaphoretic. 
Examination of his heart and lungs is unremarkable except for his 
tachycardia. An EKG reveals an acute anterior myocardial infarction with 
ST segment elevation in the precordial leads. 
Standard workup 
required to 
diagnose the 
condition 
• History consistent with a diagnosis of an acute myocardial infarction 
• EKG documentation of ST segment elevation characteristic of 
evolving acute myocardial infarction 
Criteria that 
must be met for 
a typical patient 
to be eligible 
• History consistent with a diagnosis of an acute myocardial infarction 
• EKG documentation of ST segment elevation characteristic of 
evolving acute myocardial infarction 
• Confirmation of myocardial injury with elevated cardiac enzymes 
(e.g., CK-MB, troponin) 
Criteria for 
successful 
completion of 
care for a typical 
patient 
• Subsidence of acute symptoms 
• Recovery from acute interventions and their sequelae 
• Discharge from hospital 
• Completion of post-infarction rehabilitation 
• First year of follow-up is included in ECR 
• Lifetime follow-up for coronary artery disease is not included in this 
ECR 
• Coronary artery bypass surgery terminates this ECR 
Notes: EKG = electrocardiogram, CK–MB = creatine kinase–MB. 
Source: Authors’ analysis. 
 
 
The ECR boundary development raises two issues for further discussion: 1) the 
choice of a typical patient as the focus for the ECR and 2) the boundaries of conditions 
with unclear beginning and end points. 
 
Using a Typical Patient as the Focus for the ECR 
Because patient attributes can change treatment regimens, it is necessary to agree on a 
patient type before constructing an ECR. In practice, this typical patient may actually be 
in the vast minority of patients with a given condition. In the case of diabetes mellitus 
type 2, the working group estimated that only a small percentage of all diabetes patients 
would fall under the base ECR—most patients have some comorbidity. In this instance, 
comorbidities are a critical issue: a diabetic with macrovascular disease can increase the 
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 average cost of care by 300 percent.5 Such factors must be incorporated into the case rate 
to prevent any problems with risk selection. To this end, working groups identified factors 
like comorbidities, clinical status, and demographics that must be empirically tested to 
determine their influence on costs (Table 4). Moving forward, the Prometheus team will 
conduct data modeling to determine the extent to which these indicators will change the 
scope (and reimbursement level) associated with a given ECR. 
 
 
Table 4. Factors that May Require Increased Services Beyond 
the Core ECR for ST Segment Elevated Myocardial Infarction
Factors 
Acute cardiac dysrhythmias requiring mechanical intervention (e.g., pacemaker) 
Acute pump failure requiring mechanical intervention (e.g., intra-aortic balloon pump) 
Age 
Chronic cardiac dysrhythmias 
Chronic heart failure 
Diabetes 
Dyslipidemia 
Gender 
Hypertension 
Obesity 
Pulmonary disease/respiratory failure 
Source: Authors’ analysis. 
 
 
Determination of ECR Beginning and End Points 
Physicians may be challenged in making a definitive clinical judgment about the beginning 
and end points of some conditions, as illustrated in the development of an ECR for heart 
failure, a chronic progressive illness. The Prometheus ECR is restricted to non-ischemic 
stage C heart failure, where the patient is no longer at risk for heart failure (Stage A) or has 
a structural disorder of the heart (Stage B), but has past or current symptoms of heart 
failure associated with structural heart disease. As a result of this restricted definition, it 
becomes an easier task for a physician to objectively document the ECR trigger. As a 
corollary, monitoring and treatment will always be required for a patient with non-
ischemic stage C heart failure; consequently, the ECR must account for the appropriate 
periodic assessments for the rest of the patient’s life. 
 
In addition to providing clear beginning and end points, Prometheus must also 
differentiate between onset and maintenance ECRs. Colorectal cancer, for example, is a 
disease that is very resource-intensive once diagnosed and then requires different levels of 
follow-up depending on the patient’s response to treatment. The disease is fatal in 
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 approximately half of all patients, so many will require long-term nursing care. Without a 
differentiation in onset and maintenance ECRs, the payment system could theoretically be 
gamed by providers selecting when to care for patients in order to increase their profits. 
 
ESTIMATING THE ECR BASE 
To develop an estimate of the base ECR payment, working groups walked a typical 
patient step-by-step through the relevant clinical practice guidelines, using the following 
four questions to match costs with guidelines: 
 
1. What are the actual resources (e.g., equipment, facilities, supplies) used to provide 
the recommended care? 
2. Who is most likely to use those resources? 
3. Where might this care happen most often? 
4. How long will it take (using surrogates of evaluation and management visits for time)? 
 
Figure 1 and Tables 5 and 6 show the National Comprehensive Cancer Network’s 
(NCNN) practice guidelines for stage III colorectal cancer and services needed based on 
those practice guidelines. 
 
 
Figure 1. NCCN Practice Guidelines for Stage III Colorectal Cancer 
 
 
Source: National Comprehensive Cancer Network (http://nccn.org/professionals/physician_gls/PDF/colon.pdf), p. 6. 
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 Table 5. Standard Components of Stage III Colorectal Cancer
Component Detail Common Complications 
Workup CBC/chemistries, CEA, CT of abdomen 
and pelvis, chest CT  
Elderly/comorbid may need 
cardiac workup or clearance; 
occasionally patients with 
poor renal, cardiac, or 
pulmonary function need 
more testing 
Surgical 
resection 
Three-to-five-day stay; some patients get 
colostomy with teaching, most do not; 
occasional prolonged stay with ileus; 
occasional postoperative leaks, infections, 
and deep vein thrombolosis 
Ileus, postoperative leaks, 
pneumonia, deep vein 
thrombolosis, obstruction, 
perforation 
Chemotherapy Most will receive FOLFOX, but some 
Xeloda or 5FU/leucovorin, unless they 
are on a clinical trial. Adding Avastin in 
this setting is not standard care. 
Chemotherapy requires visits, pump 
charges, drug charges, CBC/chemistries at 
every visit, doctor or nurse practitioner 
charges at every other visit 
Dose delays increase numbers 
of visits; many patients do not 
get all 12 doses because of 
neuropathy; oxaliplatin 
allergies can occur in around 
5 percent; 5 percent to 10 
percent of patients are 
hospitalized for three to 10 
days with diarrhea (mostly 
elderly) 
Surveillance Visit every three to six months; CEA 
every three to six months; CT scans of 
colon, abdomen, and pelvis every year for 
three consecutive years for higher-risk 
patients. 
Observation patients may 
have extra tests provoked by 
false positive surveillance tests 
Notes: CBC = complete blood count, CEA = carcinoembryonic antigen, CT = computerized tomography, 
FOLFOX = fluorouracil (5FU) and oxaliplatin 
Source: Authors’ analysis. 
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 Table 6. Visits Required to Treat Stage III Colorectal Cancer 
Activity Frequency* Person 
Colonoscopy 1 Gastroenterologist and 
primary care provider 
counseling on need for 
colonoscopy 
Visit to review biopsy 1 Gastroenterologist 
Appointment regarding surgery 1 Surgeon 
Hospital stay and surgery 3 to 5 days Surgeon and hospital staff 
Review data for stage III disease 1 Medical oncologist 
Visit social worker 1 Social worker 
Visit chemo nurse for teaching 1 Chemotherapy nurse 
Decide on drug therapy 1 Medical oncologist 
Lab for pre-chemo CBC, CMP, liver, CEA 1 Lab 
Meet with clinical trial staff regarding protocol 1 Trial staff 
Chemotherapy and follow-up visit every 
two weeks 
24 Medical oncologist, chemo 
nurse 
Potential problems: nausea, diarrhea, fever, etc. 3 Medical oncologist, nurse 
One month post therapy: review drug therapy 
and survivorship likelihood 
1 Medical oncologist 
Follow-up visit every 3 months 4 Medical oncologist 
Disease and case management Ongoing Medical oncologist and/or 
primary care provider 
* Frequency refers to visits unless bed days are specified for hospital stays. 
Source: Authors’ analysis. 
 
 
Adjusting ECRs for Complications and Ex Ante Factors 
For many conditions, a significant number of treatment decisions depend on the 
progression of the condition and the patient’s reaction to treatment. These decision points 
must be clearly delineated and factored into the case rates. For each condition, the 
working group identified a set of common complications that will change the services 
required. (See Table 5 for common complications associated with stage III colorectal 
cancer.) Future data modeling efforts will determine how the identified complications 
change the total cost of care. Where necessary, ECRs will be modified by adding a branch 
to the case rate decision tree. As complications develop, both the scorecard and the price 
paid for services rendered will change accordingly. 
 
The goal of the data modeling exercise is to adjust payments for complications 
outside the provider’s control that will increase required services beyond the core ECR. 
Such a step will help prevent risk selection problems. In theory, ECRs do not fully adjust 
for changes in patient status during treatment that are the result of care provided. A central 
tenet of ECRs is to separate technical risk from probability risk and to hold physicians 
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 accountable for the former but not the latter.6 As a result, providers will carry some 
financial risk for patient outcomes that are the result of poor quality care. Separating 
outcomes inside and outside a provider’s control and determining how much 
reimbursement is necessary to mitigate unnecessary downside risk are issues that must be 
monitored and revisited as Prometheus moves into its pilot phase. 
 
Limitations of Clinical Guidelines 
Work to date suggests clinical guidelines are necessary, but not always sufficient, to create 
a base ECR. Guidelines can use language that defers to a doctor’s discretion, such as, “Use 
treatment X, when appropriate.” This can make it difficult to determine the resources 
necessary to provide recommended care. Where the best available evidence or expert 
consensus does not provide sufficient information, empirical data must be used to fill in 
knowledge gaps. In these cases, data modeling will help to determine where ECRs can 
provide sufficient flexibility to physicians without having significant impact on the final 
case rate. For example, clinical guidelines are often not specific in detailing the amount of 
case management and follow-up required to treat a given condition. However, if the final 
ECR rate is not sensitive to wide variation in follow-up time, this becomes much less of 
an issue. Alternatively, examining cost data with high compliance rates may show a more 
consistent approach to case management as done by best-practice providers. 
 
ESTABLISHING MEASURES TO EVALUATE CLINICAL PERFORMANCE 
An essential component of the ECR is the performance withhold. Provider performance 
will be tracked using two methods: 1) the Prometheus scorecard, which is currently being 
designed, will include measures of care process, outcomes, and patient experience and 2) 
normal claims activity. Tracking claims can play an important a role in assessing provider 
performance—as much as the scorecard—because appropriate performance on a condition 
can potentially only be known by looking at what services were delivered (or not 
delivered) to the patient. For example, measuring the right care for back pain is effectively 
accomplished by using claims data to identify services that should (and, more important, 
should not) have been provided. Conversely, depression typically has very few encounters, 
which provide limited detail on whether the patient’s status has changed. In this case, 
using a standardized clinical assessment tool is necessary to determine a patient’s status. 
 
To ensure the Prometheus scorecards are regarded positively by physicians, team 
members will provide the following guidance about measures. 
 
What Results Should Be Measured? 
Poor measures can drive poor outcomes. Physicians involved in the working groups 
identified eye exams for diabetics as a classic example of a measure that places emphasis on 
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 treating a symptom of poor care rather than managing a disease properly. Where expert 
bodies have not already provided guidance, choosing performance measures that drive 
desired behavior can be challenging.7 Many working group members felt the scorecard 
should not shy away from using outcome measures. In the worst cases, process measures 
can handcuff doctors and create inefficiencies. As stated in the introduction to the 
American College of Cardiology/American Heart Association clinical guidelines: “These 
guidelines attempt to meet the need of most patients in most circumstances.”8 Doctors 
who are aware of the evidence but are charged with the care of a patient with an 
uncommon condition should not be punished for not following guidelines. One way to 
handle such issues is to focus on outcomes and avoid process measures where clinical 
guidelines call for flexibility and a physician’s best judgment. 
 
How Should Results Be Measured? 
In the past, measures such as eye exams were used because data were readily available 
through claims databases. Today, electronic medical records have made it easier for third 
parties to focus on the right performance measures, including clinical data such as 
hemoglobin A1c levels for diabetics. As a result, Prometheus should plan on collecting 
both claims data and clinical data to fill its scorecard. 
 
How Should Measures Be Scored and Used for Incentive Purposes? 
Once Prometheus has the right measures and measurement systems, the question of 
scoring results will arise. Team members debated three general options for scoring 
performance: 1) as discrete variables, each with a specific threshold; 2) as joint variables 
with an all-or-nothing target; or 3) as score relative to others’ performance. 
 
Many of the physicians in the group felt that the latter two options could be 
discouraging to a large percentage of physicians and may not promote significant 
improvement. Instead, members favored having a number of measures on the scorecard, 
with Prometheus heavily weighting those measures determined by experts to be most 
closely associated with good care and outcomes. Working groups did emphasize that if 
Prometheus pursued this path, scorecard goals must be reasonable and account for patient 
choice. Setting targets at the ideal (e.g., lipids at 70 for 100% of myocardial infarction 
patients) is unreasonable and may cause physicians to neglect making substantive efforts to 
reach targets in the scorecard. The scorecard must also deal with the reality that patients 
can choose their own care paths. If someone declines care, this should immediately close 
the case rate and remove the patient’s data from the scorecard. Finally, to promote the 
concept of physician control and responsibility, physicians should have the option to be 
evaluated at the individual level or at the practice level. 
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 NEXT STEPS 
Data Modeling 
Data modeling activities will determine the final value of the ECRs used in a future pilot. 
The Prometheus data modeling team expects to find that the variation in episode costs 
will be significant. As a result, the team will seek to address this problem by: adjusting case 
rates for severity, using the risk factors identified by working groups; eliminating cost data 
with low compliance rates, or, conversely, only using data with 100 percent compliance 
rates; and removing outliers (i.e., dropping top and bottom 5% of providers from the 
analysis). Data for the modeling will come from both clinical and claims databases. 
 
Development of Additional ECRs 
To aid in ECR creation, working groups designed an ECR development template as an 
important first step (Appendix A). Members suggested that future development efforts 
should focus on a “building block” approach to ECR creation. This would apply 
specifically to ECRs with clear patient management hand-offs. Each building block could 
be looked at as a smaller, self-contained episode. For example, a surgical episode is a 
building block of the overall stage III colon cancer ECR. Development of a series of 
technical episodes that can become modules to plug into case rates when warranted will 
reduce overall ECR development time. 
 
There are other outstanding questions for the pilot phase of the project. First, how 
many ECRs are necessary to make Prometheus a compelling payment alternative? The 
Institute for Clinical Systems Improvement currently has clinical guidelines for 53 different 
conditions. However, if data modeling indicates a need for more specific ECRs to 
eliminate the problem of average risk, then the total number of ECRs could multiply into 
the hundreds, or even thousands, very quickly. If this were to happen, Prometheus could 
choose to focus on the conditions where a new payment system can have the greatest 
impact and let current payment models cover the remaining conditions. 
 
Prometheus needs a clear method to prioritize the development of future ECRs. 
The Prometheus team suggests placing conditions into the following framework, in the 
following order: 
 
1. high prevalence and high cost per event, 
2. high prevalence and moderate cost per event, 
3. moderate prevalence and high cost per event, and 
4. moderate prevalence and moderate cost per event. 
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 Appendix B provides a list of surgical conditions that may be well suited to future 
ECR development. 
 
Finally, the Prometheus team must consider how to keep ECRs updated as clinical 
guidelines change. To date, Prometheus has relied on volunteer time from physicians 
dedicated to payment reform. This commitment will not continue indefinitely. Working 
group members suggested that Prometheus investigate other business models that rely on 
networked volunteers to contribute to the overall effort (e.g., the Linux community). 
Working group members also noted that future ECR development should involve 
interdisciplinary teams (e.g., hospital representatives, pharmacists) and not just physicians. 
 
Pilot Projects 
In 2007, Prometheus will select up to four pilot sites and work with local stakeholders to 
prepare each site for implementation. Current candidates include Brockton, Mass.; 
Chicago; Memphis, Tenn.; Philadelphia; and San Francisco. Prometheus also expects to 
develop an additional 50 to 60 ECRs during the next three years to increase the scope of 
the pilots and cover an increasing portion of the total care delivered in any community. 
 
CONCLUSION 
Work to date has shown it is possible to create a working set of ECRs. Moving forward, 
Prometheus must determine if the product can successfully achieve its ends: a limitation 
on physician-induced demand, a reduction in risk selection problems, the promotion of 
clinical integration, and the delivery of recommended, high-quality care. The pilot 
projects present the opportunity to measure progress against these goals and set the stage 
for a fuller implementation of the Prometheus payment system. 
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 NOTES 
 
1 Prometheus Payment was named for the Titan, in Greek mythology, who defied Zeus by 
bringing fire to mankind. The term “Promethean” refers to events or people of great creativity, 
intellect, and boldness. 
2 Because one of the working groups focused on preventive care, the working groups agreed 
to use the term “condition” in lieu of “disease state.” 
3 Institute of Medicine, Crossing the Quality Chasm: A New Health System for the Twenty-first 
Century (Washington, D.C.: National Academies Press, 2001).
4 The cardiac care group chose heart failure as one of its ECRs, despite uncertainty around 
when the case rate should begin and end. Lessons learned here can be applied to other disease 
states with complex beginning and end points. 
5 T. P. Gilmer, P. J. O’Connor, W. A. Rush et al., “Predictors of Health Care Costs in Adults 
with Diabetes,” Diabetes Care, Jan. 2005 28(1):59–64; S. R. Gandra, L. W. Lawrence, B. M. 
Parasuraman et al., “Total and Component Health Care Costs in a Non-Medicare HMO 
Population of Patients with and without Type 2 Diabetes and with and without Macrovascular 
Disease,” Journal of Managed Care Pharmacy, Sept. 2006 12(7):546–54. 
6 Technical risk is the “care production” risk that is controllable by the provider and a result of 
the provider’s technical skills. Probability risk is the classic form of insurance risk that is caused by the 
likelihood of a negative event occurring to a patient as a result of that patient’s genes, health status, 
and any external event not controllable by the provider (e.g., contracting a virus or breaking a leg). 
7 For some conditions, a solid set of performance measures already exists. For example, the 
American College of Cardiology/American Heart Association issued a set of clinical performance 
measures for adults with ST-elevation myocardial infarction in 2006. 
8 See http://www.acc.org/qualityandscience/clinical/guidelines/stemi/Guideline1/ 
Preamble.htm#1top. 
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 APPENDIX A. ECR WORKSHEET AND ECR WORKING GROUP MEMBERS 
 
1. Condition and/or procedure to be covered by the ECR. 
2. Expected impact in cost-efficiency and quality of paying for care with an ECR. 
That is, if the case rate works to positively modify behavior, what would change 
relative to status quo? What really matters in making a change in this clinical area? 
3. What are the current barriers in the current payment system that may prevent the 
“right thing” from being done? 
4. Clinical description of a typical patient covered by the core ECR. 
5. Standard workup required to diagnose and characterize the condition and establish 
the appropriateness and scope of the procedure covered by the ECR. 
6. Criteria that must be met for a typical patient to be eligible for coverage by the 
core evidence-informed case rate. 
7. Criteria for successful completion of care for a typical patient covered by the 
core ECR. 
8. Listing of clear and specific hand-offs between clinicians during care of the patient. 
Include only those hand-offs during which the provider responsible for the 
management of the patient changes (e.g., oncologist handing off the patient to the 
surgeon or hospital for a colon resection). 
9. Type and intensity of services required by clinical practice guidelines to care for a 
typical patient covered by the core ECR. To the extent applicable, note where 
hand-offs occur, as follows: 
 
Standard 
component 
of care 
Definitions 
of the 
component 
Detail of the 
component 
Modifiers 
due to patient 
characteristic 
Common 
complications 
Duration 
of the 
component 
 
10. Listing of typical caregivers and frequency of care type. Make sure to include an 
allowance for the management of the case by a physician, if appropriate, and for 
nurse-led disease and care management activities, as follows: 
 
Activity Frequency Person/organization 
 
11. Ex ante factors (e.g., comorbidities, clinical status, disease progression) that increase 
required services beyond those covered by the core ECR. 
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 12. Complications associated with the covered condition and/or procedure or with its 
diagnosis and/or treatment that increase required services beyond those covered by 
the core ECR. 
 
ECR Working Group Members 
Cancer: Linda Bosserman, M.D., Dawn Holcombe, M.B.A., Sara Perkel, M.B.A., 
Peter Eisenberg, M.D., Lee Schwartzberg, M.D., Chris Desch, M.D. 
Cardiac care: Mort Arnsdorff, M.D., Joe Messer, M.D., Michael Pine, M.D., 
Bonnie Weiner, M.D., Janet Wright, M.D. 
Chronic and preventive care: Peter Basch, M.D., Patrick O’Connor, M.D., Leif Solberg, M.D. 
Orthopedics: Michael London, M.D., Robert Haralson, M.D. 
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 APPENDIX B. SURGICAL PROCEDURES FOR ECR DEVELOPMENT 
 
Prospective global payment for episodes of clinical care is suited for many surgical 
situations. Many surgical episodes have a definable beginning of care and a definable point 
where follow-up is complete and additional costs and management are not necessary. The 
following procedures are particularly well suited for consideration of ECR development 
within the Prometheus payment strategy. These procedures have been chosen because 
they constitute high-volume procedures or are modest-volume procedures that carry very 
high costs. All have the potential for dramatic improvement in expenditures without 
compromising quality of care. 
 
Procedures 
Total Number
of Cases (2004) Length of Stay Billed Charges
Gastrointestinal  
Partial gastrectomy 10,222 13.3 days $72,000
Total gastrectomy 3,875 15.6 days $97,000
Open gastric bypass 23,221 3.2 days $33,500
Lap gastric bypass 13,868 2.7 days $32,000
Lap cholecystectomy 323,399 4 days $24,600
Open appendectomy 161,533 3.3 days $18,700
Lap appendectomy 135,473 2.4 days $19,000
Colon resection 320,437 10 days $50,000
Major pancreatectomy 11,174 14 days $82,000
Hepatic resection 3,025 9.5 days $69,000
Cardiothoracic  
Esophagectomy 2,747 17 days $107,000
Open heart procedures 357,324 10 days $95,000
Open lung resection 38,224 9 days $54,000
Head and neck  
Total laryngectomy 1,304 12.3 days $57,750
Radical laryngectomy 1,757 11.9 days $59,000
Radical neck dissection 9,481 3.6 days $25,000
Obstetrics-Gynecology  
Abdominal hysterectomy 389,109 3.1 days $16,500
Vaginal hysterectomy 184,896 2 days $14,750
C-section 1,246,978 3.7 days $13,300
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 Procedures 
Total Number
of Cases (2004) Length of Stay Billed Charges
Orthopedic  
Total knee arthroplasty 431,485 4 days $33,700
Total hip arthroplasty 328,283 5 days $37,000
Peripheral vascular  
Major vascular procedures 113,670 8.3 days $54,000
Carotid endarterectomy 121,470 2.7 days $22,000
Urology  
Nephrectomy 44,871 5.6 days $34,000
Radical prostatectomy 55,945 3 days $22,000
Total cystectomy 7,117 10.9 days $60,000
Source: Healthcare Cost and Utilization Project Data—2004-2006, AHRQ. 
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 APPENDIX C. GLOSSARY 
 
Ex ante clinical factors: Patient-specific factors known up front as a result of an initial 
examination and diagnosis and that can have an impact on resource consumption. For 
example, a morbidly obese patient requiring a hip replacement will require a longer time 
in physical therapy than an average patient. 
 
Risk/severity-adjustments: Patients with ex ante factors that are related to increased resource 
consumption will trigger an adjustment in the ECR to reflect the higher level of severity 
and/or the greater risk for warranted increases in resource consumption. These adjustments 
are arrived at by analyzing large databases of claims and medical records to determine the 
strength of associations between certain ex ante factors and resource consumption. 
 
Care delivery process: Process through which a patient receives care for a condition by all 
providers who interact directly or indirectly with that patient. 
 
Physician-induced demand/Unwarranted variation: Resource consumption varies from patient 
to patient and that variation can be split into two components: warranted and 
unwarranted. Warranted variation is caused by ex ante factors—clinical factors that are 
brought into the care delivery process by the patient. Unwarranted variation is introduced 
by errors of overuse, underuse, misuse, and other technical competence defects committed 
by one or more care providers during the care delivery process, which can lead to 
unneeded “physician-induced” services. 
 
Clinical integration: Result of providers involved in the care delivery process working as a 
team although no formal legal contract necessarily binds them together to do so. 
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